Expansion opportunities Hardy Diagnostics has a growing portfolio of microbiology products and recent partnerships with NEMIS Technologies and Gradientech for rapid pathogen detection and FDA-classified devices. Sales teams can target labs expanding rapid testing capabilities and on-site diagnostics, offering complementary products and integration with existing workflows.

Strategic partnerships Recent collaborations with Gradientech for QuickMIC and NEMIS Technologies for rapid on-site detection indicate a focus on expanding capabilities through partnerships. Business development can explore co-marketing, bundled solutions, and channel partnerships with distributors and labs seeking turnkey diagnostic ecosystems.

Regulatory and quality strengths FDA-licensed medical device manufacturer with ISO 13485 certification signals reliability and compliance. Sales opportunities exist in institutions prioritizing compliant supply of microbiology consumables and devices, including government and large healthcare networks that require robust quality management.

Global and scaling potential As a 100% employee-owned, mid-sized company with international product relevance, Hardy Diagnostics can leverage its global impact to pursue larger hospital networks, research institutions, and public health programs seeking scalable, trusted microbiology solutions with strong customer support.

Innovation momentum Product launches such as Enrichment Broth for Candida auris detection and CompactDry TCR demonstrate ongoing R&D and portfolio expansion. Sales outreach can emphasize new performance capabilities, faster turnaround, and disease resistance pathway detection to win early adoption deals and renewals.